A Phase 1B Study Evaluating RO7082859 in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed Refractory Follicular Lymphoma (R/R FL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2019
At a glance
- Drugs RO 7082859 (Primary) ; Cyclophosphamide; Doxorubicin; Obinutuzumab; Prednisone; Rituximab; Tocilizumab; Vincristine
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 23 Jan 2019 Planned End Date changed from 1 Jun 2023 to 17 Jun 2023.
- 23 Jan 2019 Planned primary completion date changed from 1 Jun 2023 to 17 Jun 2023.
- 19 Mar 2018 New trial record